| Expression pattern: |
UP |
| Associated gene: |
FGF7 |
| Associated microRNA: |
miR‐1236‐3p |
| Biological function: |
promotes proliferation, migration, invasion and glycolysis; inhibits apoptosis; promotes tumor growth in vivo |
| Molecular mechanism: |
ceRNA mechanism: circADAM9 sponges miR-1236-3p to relieve repression of FGF7 |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); glycolysis (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Transfection; Colony Formation Assay; EdU Staining; Wound Healing Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model |
| Clinical significance: |
potential prognostic biomarker and therapeutic target for BC patients |
| Description: |
circADAM9 is up-regulated in breast cancer tissues and cell lines and mainly localizes in the cytoplasm. It promotes malignant behaviors and glycolysis and inhibits apoptosis by sponging miR-1236-3p to upregulate FGF7, and its knockdown suppresses tumor growth in a cell line-derived xenograft model. |
| Confidence score: |
0.8327 |